Using this concept, Thoreau et al. conjugated two targeting ligands, an RGD peptide (cyclic RGDyK) recognizing CD51 and a heptapeptide (ATWLPPR) recognizing NRP-1, and used imaging to demonstrate enhanced tumor-targeting efficiency and tumor accumulation [115]. The gene discussed is ITGAV; the disease is neoplasm.